

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM716433

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	Release of Security Interest in Intellectual Property		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Perceptive Credit Holdings II, LP, as Administrative Agent		03/23/2022	Limited Partnership: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	ADMA Biologics, Inc.		
<b>Street Address:</b>	5800 Park of Commerce Blvd., NW		
<b>City:</b>	Boca Raton		
<b>State/Country:</b>	FLORIDA		
<b>Postal Code:</b>	33487		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>Name:</b>	ADMA Biomanufacturing, LLC		
<b>Street Address:</b>	5800 Park of Commerce Blvd., NW		
<b>City:</b>	Boca Raton		
<b>State/Country:</b>	FLORIDA		
<b>Postal Code:</b>	33487		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 7</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	3015857	CIVACIR	
<b>Registration Number:</b>	2635779	NABI-HB	
<b>Registration Number:</b>	4430011	BIVIGAM CARES	
<b>Registration Number:</b>	4495929	FOR UNCOMPROMISED LIVING	
<b>Registration Number:</b>	4404516	INSPIRED SUPPORT FOR THE PI COMMUNITY	
<b>Registration Number:</b>	4318477	BIVIGAM	
<b>Registration Number:</b>	5967728	ASCENIV	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2027393001		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2027395866		
<b>Email:</b>	felicia.gordon@morganlewis.com		

CH \$190.00 3015857

**Correspondent Name:** Morgan, Lewis & Bockius LLP  
**Address Line 1:** 1111 Pennsylvania Avenue, NW  
**Address Line 4:** Washington, D.C. 20004

**ATTORNEY DOCKET NUMBER:** 124650.0034

**NAME OF SUBMITTER:** Felicia D. Gordon

**SIGNATURE:** /Felicia D. Gordon/

**DATE SIGNED:** 03/24/2022

**Total Attachments: 14**

source=ADMA\_Hayfin - Perceptive Credit Holdings II LP - Release of IP Security Interest (Executed)#page1.tif  
source=ADMA\_Hayfin - Perceptive Credit Holdings II LP - Release of IP Security Interest (Executed)#page2.tif  
source=ADMA\_Hayfin - Perceptive Credit Holdings II LP - Release of IP Security Interest (Executed)#page3.tif  
source=ADMA\_Hayfin - Perceptive Credit Holdings II LP - Release of IP Security Interest (Executed)#page4.tif  
source=ADMA\_Hayfin - Perceptive Credit Holdings II LP - Release of IP Security Interest (Executed)#page5.tif  
source=ADMA\_Hayfin - Perceptive Credit Holdings II LP - Release of IP Security Interest (Executed)#page6.tif  
source=ADMA\_Hayfin - Perceptive Credit Holdings II LP - Release of IP Security Interest (Executed)#page7.tif  
source=ADMA\_Hayfin - Perceptive Credit Holdings II LP - Release of IP Security Interest (Executed)#page8.tif  
source=ADMA\_Hayfin - Perceptive Credit Holdings II LP - Release of IP Security Interest (Executed)#page9.tif  
source=ADMA\_Hayfin - Perceptive Credit Holdings II LP - Release of IP Security Interest (Executed)#page10.tif  
source=ADMA\_Hayfin - Perceptive Credit Holdings II LP - Release of IP Security Interest (Executed)#page11.tif  
source=ADMA\_Hayfin - Perceptive Credit Holdings II LP - Release of IP Security Interest (Executed)#page12.tif  
source=ADMA\_Hayfin - Perceptive Credit Holdings II LP - Release of IP Security Interest (Executed)#page13.tif  
source=ADMA\_Hayfin - Perceptive Credit Holdings II LP - Release of IP Security Interest (Executed)#page14.tif

**RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY**

This **RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY** (the “Release”) is made as of March 23, 2022, by **PERCEPTIVE CREDIT HOLDINGS II, LP**, as administrative agent for all Lenders that are party to the Credit Agreement as defined herein (the “Agent”), in favor of **ADMA BIOLOGICS, INC., ADMA BIOMANUFACTURING, LLC** and all other Grantors under the Credit Agreement (the “Grantors”).

WHEREAS, the Grantors entered into that certain Credit Agreement and Guarantee, dated as of February 11, 2019, among certain of the Grantors, the Agent, the Lenders and the other parties thereto, as such was amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof (the “Credit Agreement”), whereby the Lenders agreed to make certain loans and to extend certain letters of credit to the Grantors and certain related parties (collectively, the “Loans”);

WHEREAS, pursuant to the Credit Agreement, and as a condition of the Lenders making the Loans, the Grantors entered into that certain Security Agreement, dated as of February 11, 2019, among certain of the Grantors and the Agent for the benefit of the Lenders, and all annexes, exhibits or schedules thereto, as each may have been amended, restated, supplemented or otherwise modified from time to time (the “Security Agreement”), whereby the Grantors were obligated to enter into certain security agreements, instruments and documents in favor of Agent;

WHEREAS, in furtherance of the Credit Agreements and pursuant to the Security Agreement, the Grantors executed and delivered the following security agreements, instruments and documents in favor of Agent, including, without limitation, the following:

- (i) Patent Security Agreement, dated as of February 11, 2019, by ADMA Biologics, Inc. in favor of Agent, as recorded with the U.S. Patent and Trademark Office (the “USPTO”) on February 12, 2019 at Reel 048309/Frame 0289;
- (ii) Trademark Security Agreement, dated as of February 11, 2019, by ADMA Biologics, Inc. and ADMA Biomanufacturing, LLC in favor of Agent, as recorded with the USPTO on February 12, 2019 at Reel 006560/Frame 0026;
- (iii) Patent Security Agreement, dated as of March 20, 2020, by ADMA Biologics, Inc. in favor of Agent, as recorded with the USPTO on March 27, 2020 at Reel 052252/Frame 0041;
- (iv) Trademark Security Agreement, dated as of March 20, 2020, by ADMA Biologics, Inc. and ADMA Biomanufacturing, LLC in favor of Agent, as recorded with the USPTO on April 1, 2020 at Reel 006904/Frame 0518; and
- (v) Patent Security Agreement, dated as of January 15, 2021, by ADMA Biologics, Inc. in favor of Agent, as recorded with the USPTO on January 15, 2021 at Reel 055009/Frame 0755 (collectively, the “Intellectual Property Security Agreements”);

WHEREAS, pursuant to the Intellectual Property Security Agreements, the Grantors granted the Agent, on behalf of itself and the Lenders, a continuing security interest in all of each applicable Grantor’s right, title and interest in, to and under certain intellectual property Collateral, including, without limitation, the patents and patent applications, and trademark registrations and applications for trademark registration

identified on Exhibit 1 attached hereto (collectively, the “Intellectual Property Collateral”);

WHEREAS, the Grantors have satisfied in full the terms of the Credit Agreement and Security Agreement and have requested that the Agent, on behalf of itself and the Lenders, (a) terminate and release the security interest in the Intellectual Property Collateral, and (b) provide a document suitable for recording with the USPTO for the release, relinquishment and discharge of its security interest in the Intellectual Property Collateral; and

WHEREAS, the Loans and all other obligations under the Credit Agreement and Security Agreement have been paid in full or fulfilled, and there are no outstanding obligations remaining due and owing under the Credit Agreement and Security Agreement, which have been terminated, the Agent, on behalf of itself and the Lenders, desires to terminate and grant a release of its security interest in the Intellectual Property Collateral and to terminate and release the Intellectual Property Security Agreements as provided in this Release.

NOW THEREFORE, for good and valuable consideration previously tendered by the Grantors, the receipt and sufficiency of which are hereby acknowledged, the Agent, on behalf of itself and the Lenders, does hereby agree as follows:

1. The Agent, on behalf of itself and the Lenders, hereby: (a) terminates the Intellectual Property Security Agreements; (b) releases, relinquishes, terminates and discharges, without recourse, its security interest in the Intellectual Property Collateral in its entirety; and (c) retransfers and reassigns to the applicable Grantors any and all right, title and interest of any nature whatsoever which it may hold in, to or under any of the Intellectual Property Collateral, including, without limitation, the patents and patent applications and trademark registrations and applications for trademark registration identified on Exhibit 1 attached hereto, and all associated common law rights and goodwill appurtenant thereto.

2. The Agent, on behalf of itself and the Lenders, authorizes the Grantors to record this Release with the USPTO and any other applicable governmental authority.

3. At the request and sole expense of the Grantors, the Agent, on behalf of itself and the Lenders, agrees to execute, acknowledge and deliver all such further instruments and to take all such further actions necessary to carry out the purposes of this Release.


4. All capitalized terms used but not defined in the Release shall have the meaning set forth in the Credit Agreement, Security Agreement, and/or Intellectual Property Security Agreements, as applicable. The Release shall be governed by, and construed in accordance with, the laws of the United States and the State of New York, without giving effect to any conflicts of law principles.


*[Signature page follows]*

IN WITNESS WHEREOF, the undersigned has caused this Release to be duly executed as of the date first written above.

**PERCEPTIVE CREDIT HOLDINGS II, LP,**  
as Agent

By: **PERCEPTIVE CREDIT OPPORTUNITIES GP, LLC,**  
its general partner

DocuSigned by:  
  
By: \_\_\_\_\_  
79FBFAAB0290476...  
Name: Sandeep Dixit  
Title: Chief Credit Officer

DocuSigned by:  
  
By: \_\_\_\_\_  
B0540D0B5370401...  
Name: Sam Chawla  
Title: Portfolio Manager

[Signature Page to Release of Security Interest in Intellectual Property]

**TRADEMARK**  
**REEL: 007670 FRAME: 0060**

# **EXHIBIT 1**

# PATENTS

**PATENTS**Issued Patents of each Grantor

<b>Patent /Application</b>	<b>Serial/ Registration Number</b>	<b>Filing/ Registration Date</b>	<b>Grantor/Owner</b>	<b>Filing Location</b>
COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY	Patent No. 9,107,906 B1	08/18/2015	ADMA Biologics, Inc.	USA
	Patent No. 9,714,283 B2	07/25/2017	ADMA Biologics, Inc.	USA
	Patent No. 9,815,886 B2	11/14/2017	ADMA Biologics, Inc.	USA
	Patent No. 9,969,793 B2	05/15/2018	ADMA Biologics, Inc.	USA

Pending Patent Applications of each Grantor

<b>Patent /Application</b>	<b>Serial/ Registration Number</b>	<b>Filing/ Registration Date</b>	<b>Grantor/Owner</b>	<b>Filing Location</b>
COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY	App. No. 14/592,727	01/08/2015	ADMA Biologics, Inc.	USA
	App. No. 14/790,872	07/02/2015	ADMA Biologics, Inc.	USA
	App. No. 14/592,721	01/08/2015	ADMA Biologics, Inc.	USA
	App. No. 15/811,486	05/14/2018	ADMA Biologics, Inc.	USA
	App. No. 62/069589	10/28/2014	ADMA Biologics, Inc.	USA
	App. No. PCT/US2015/057715	10/28/2015	ADMA Biologics, Inc.	PCT
	App. No. 242156	10/19/2015	ADMA Biologics, Inc.	Israel
	App. No. 2015145033	10/20/2015	ADMA Biologics, Inc.	Russia
	App. No. MX/a/2015/014751	10/21/2015	ADMA Biologics, Inc.	Mexico



Patent /Application	Serial/ Registration Number	Filing/ Registration Date	Grantor/Owner	Filing Location
	App. No. 15190963.7	10/22/2015	ADMA Biologics, Inc.	European Patent
	App. No. 16113712.2	10/22/2015	ADMA Biologics, Inc.	Hong Kong
	App. No. 2015246157	10/23/2015	ADMA Biologics, Inc.	Australia
	App. No. 2910491	10/23/2015	ADMA Biologics, Inc.	Canada
	App. No. 2015/07987	10/27/2015	ADMA Biologics, Inc.	South Africa
	App. No. 2017/07303	10/26/2017	ADMA Biologics, Inc.	South Africa
	App. No. BR1020150273878	10/28/2015	ADMA Biologics, Inc.	Brazil
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection	App. No. 15/460,147	03/15/2017	ADMA Biologics, Inc.	USA
	App. No. 2018201803	03/14/2018	ADMA Biologics, Inc	Australia
	App. No. 102018005192-0	03/15/2018	ADMA Biologics, Inc	Brazil
	App. No. 2998067	03/13/2018	ADMA Biologics, Inc	Canada
	App. No. 18161907.3	03/15/2018	ADMA Biologics, Inc	Europe
	App. No. 258116	03/14/2018	ADMA Biologics, Inc	Israel
	App. No. MX/a/2018/003159	03/14/2018	ADMA Biologics, Inc	Mexico
	App. No. 2018-109264	03/15/2018	ADMA Biologics, Inc	Russia
	App. No. PCT/US2018/022701	03/15/2018	ADMA Biologics, Inc	PCT

Licenses of each Grantor Related to Issued Patents and Pending Patent Applications

License Agreement by and between ADMA Biologics, Inc. (as Licensor) and BiotestAktiengesellschaft, a corporation organized under the laws of Germany, dated as of 12/31/2012 (ADMA's approval is required prior to any sublicense).

**PATENTS**Patent Registrations and Applications

Patent	Reg. No. (App. No.)	Reg. Date (App. Date)	Owner
COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY	15/978,692	5/14/2018	ADMA Biologics, Inc.
	9,714,283 B2	07/25/2017	ADMA Biologics, Inc.
	9,815,886 B2	11/14/2017	ADMA Biologics, Inc.
	9,969,793 B2	05/15/2018	ADMA Biologics, Inc.
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection	10,259,865	4/16/2010	ADMA Biologics, Inc.
	16/384,334	4/15/2019	ADMA Biologics, Inc.
AUTOMATED DOCUMENT MANAGEMENT SYSTEM IMMUNODEFICIENCY	16/526,106	7/30/2019	ADMA Biologics, Inc.
IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS OF PRODUCTION FOR CORONAVIRUS	62/987,213	3/9/2020	ADMA Biologics, Inc.


**PATENTS**Patent Registrations and Applications

Patent	Reg. No. (App. No.)	Reg. Date (App. Date)	Owner
COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY	10,683,343 B2	06/16/2020	ADMA Biologics, Inc.
	16/901,993	06/15/2020	ADMA Biologics, Inc.
COMPOSITIONS AND METHODS FOR DETERMINING CORONAVIRUS NEUTRALIZATION TITERS	63/074,892	09/04/2020	ADMA Biologics, Inc.
	63/060,395	08/03/2020	ADMA Biologics, Inc.
IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS OF PRODUCTION FOR CORONAVIRUS	62/994,624	3/25/2020	ADMA Biologics, Inc.
IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS FOR CORONAVIRUS	63/004,759	04/03/2020	ADMA Biologics, Inc.

# **TRADEMARKS**

## TRADEMARKS

Registered Trademarks of each Grantor

Mark/Application	Serial/ Registration Number	Filing/ Registration Date	Grantor/Owner	Filing Location
ASCENIV	Register No. 1352668	5/10/2017	ADMA Biologics, Inc.	International
CIVACIR	Register No. 3,015,857	11/15/2005	ADMA BioManufacturing, LLC	USA
NABI-HB	Register No. 2,635,779	10/15/2002	ADMA BioManufacturing, LLC	USA
BIVIGAM CARES	Register No. 4,430,011	11/5/2013	ADMA BioManufacturing, LLC	USA
FOR UNCOMPROMISED LIVING	Register No. 4,495,929	03/11/2014	ADMA BioManufacturing, LLC	USA
INSPIRED SUPPORT FOR THE PI COMMUNITY  	Register No. 4,404,516	09/17/2013	ADMA BioManufacturing, LLC	USA
BIVIGAM	Register No. 4,318,477	04/09/2013	ADMA BioManufacturing, LLC	USA
NABI – HB	Register No. 829811818	01/17/2012	ADMA BioManufacturing, LLC	Brazil
NABI-HB	Register No. 3109048	01/31/2005	ADMA BioManufacturing, LLC	European Union
NABI-HB	Register No. 211681	04/13/2010	ADMA BioManufacturing, LLC	Israel

NABI-HB	Register No. 301116549	05/15/2008	ADMA BioManufacturing, LLC	Hong Kong
NABI HB	Register No. 01349353	02/16/2009	ADMA BioManufacturing, LLC	Taiwan
NABI-HB	Register No.964372	05/13/2008	ADMA BioManufacturing, LLC	International
NABI-HB	Register No. 602442	02/17/2004	Nabi Pharmaceuticals	Canada
NABI-HB	Register No. 220944	11/29/2010	Nabi Pharmaceuticals	Egypt
CIVACIR	Register No.887996	05/09/ 2006	ADMA BioManufacturing, LLC	International

- All common law trademark rights in BIVIGAM, NABI-HB and CIVACIR

Pending Trademark Applications of each Grantor

Mark/Application	Serial/ Registration Number	Filing/ Registration Date	Grantor/Owner	Filing Location
ASCENIV	App. No. 87012361	4/25/2016	ADMA Biologics, Inc.	USA

Licenses of each Grantor Related to Registered Trademarks and Pending Trademark Applications

None.

ny-1355392

**TRADEMARKS**Trademark Registrations and Applications

Trademark	Serial/Reg. No. (App. No.)	Filing/Reg. Date (App. Date)	Owner
ASCENIV	5,967,728	1/21/2020	ADMA Biologics, Inc.
CIVACIR	Register No. 3,015,857	11/15/2005	ADMA Biomanufacturing, LLC
CIVACIR	Register No. 887996	5/09/2006	ADMA Biomanufacturing, LLC